Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.57 |
| ▸ | CTSH | P09668 | 1/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | GLP1R | P43220 | 2/20 | 0.52 |
| ▸ | GCGR | P47871 | 2/20 | 0.52 |
| ▸ | GIPR | P48546 | 1/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593288 | 0.90 | C5AR1 (0.63) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30301165 | 0.89 | C5AR1 (0.67) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL29655839 | 0.89 | CXCR4 (0.63) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30609010 | 0.89 | CTSL (0.60) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30609016 | 0.89 | CTSL (0.60) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL29697153 | 0.89 | C5AR1 (0.65) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL31182480 | 0.88 | C5AR1 (0.64) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL29463744 | 0.88 | KISS1R (0.60) | C5AR1KISS1RCXCR4CAPN1CTSB | |
| SCHEMBL30609011 | 0.87 | CTSL (0.62) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30577311 | 0.87 | CTSL (0.61) | C5AR1CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345387-A1 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | HAMILTON DOUGLAS A (US) | 2025-11-13 | — | — | US | disclosed |
| US-20240083962-A1 | AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2024-03-14 | — | — | US | disclosed |
| EP-4132491-A2 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | Vasomune Therapeutics Inc. (CA) | 2023-02-15 | — | — | EP | disclosed |
| US-20230028130-A1 | Coronavirus Therapeutics and Treatment Methods | HAMILTON DOUGLAS A (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3568409-B1 | AGENT FOR PROMOTING ANGIOGENESIS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2022-12-21 | — | — | EP | disclosed |
| US-20220372095-A1 | AN AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2022-11-24 | — | — | US | disclosed |
| US-11384130-B2 | Agent for promoting angiogenesis and methods and uses thereof | VASOMUNE THERAPEUTICS INC. (CA) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028130-A1 | Coronavirus Therapeutics and Treatment Methods | SARS1, ACE2, TMPRSS2 | C5AR1 178/4885CTSL 53/4885CTSS 188/4885 |
| US-20220372095-A1 | AN AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VEGFA, PGF, FLT4 | C5AR1 55/4885CTSL 1723/4885CTSS 1801/4885 |
| US-20250345387-A1 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | SARS1, ACE2, TMPRSS2 | C5AR1 178/4885CTSL 53/4885CTSS 188/4885 |
| US-20240083962-A1 | AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VEGFA, PGF, FLT4 | C5AR1 54/4885CTSL 1851/4885CTSS 2050/4885 |
| US-11384130-B2 | Agent for promoting angiogenesis and methods and uses thereof | VEGFA, PGF, FLT4 | C5AR1 54/4885CTSL 1851/4885CTSS 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.